Bigknowledge Enterprises Inc.
TSX VENTURE : BGK

Bigknowledge Enterprises Inc.

September 30, 2005 13:07 ET

Genzyme Selects Bigknowledge's Training Solutions to Support the Roll-Out of its New CRM System

MONTREAL, CANADA--(CCNMatthews - Sept. 30, 2005) - Bigknowledge Enterprises Inc. (TSX VENTURE:BGK)

Genzyme, based in Cambridge, MA., is a leading biotechnology company focused on developing and marketing therapeutics for rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases. Genzyme is introducing a new Customer Relationship Management (CRM) system to capture key account data, expand business intelligence and automate key business processes.

Genzyme was seeking an effective and economical solution for training new users. Bigknowledge Enterprises Inc. (TSX VENTURE:BGK) created a blended learning solution, where users will take a one hour e-Learning module as a prerequisite to live instruction. The e-Learning module is designed to allow reps to master the system's basic navigation and core business processes. Bigknowledge designed a half-day, scenario-based workshop to train users on advanced topics. The blended learning solution enabled Genzyme to minimize the sales force's time off territory; reduce training expenses; provide an enduring resource for future training and as a reference tool; provide a relevant, interactive forum for users to learn about the CRM system from business owners and stakeholders.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 7,600 employees in locations spanning the globe, and 2004 revenues of $2.2 billion. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

About Bigknowledge Enterprises Inc. - www.Bigknowledge.com

Bigknowledge Enterprises Inc. is a leader in the development of customized multilingual e-Learning solutions targeted at Fortune 500 and Global 1000 corporate institutions worldwide. With over 11 years of experience in developing high quality web based training solutions, our course designs are Learner Centric, highly engaging and respectful of the local culture of our 250 global corporate clients.

Through the acquisition of Versalys, Bigknowledge has gained 20 years of experience in Instructor Led Training programs providing Blended Learning solutions to over 5,000 users annually.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information